TECH|Analyst Targets
TECH|Company Info
TECH|Insider Trading
TECH|Fundamentals
TECH|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $0.45 | - | - |
| Q3'26 | $0.53 | $0.53 | -0.8% |
| Q2'26 | $0.54 | $0.46 | -14.5% |
| Q3'25 | $0.42 | $0.42 | -0.4% |
| Q2'25 | $0.50 | $0.53 | +5.8% |
| Q1'25 | $0.51 | $0.56 | +10.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $298M | - | - |
| Q3'26 | $316M | $311M | -1.5% |
| Q2'26 | $317M | $296M | -6.5% |
| Q3'25 | - | $287M | - |
| Q2'25 | - | $317M | - |
| Q1'25 | - | $316M | - |
TECH|Monthly Returns
Market Data
TECH Stock Snapshot
- Market cap
- 11.37B
- P/E ratio
- 62.5
- Day range
- $72.48 – $72.54
- News sentiment
- 34/100 · Bearish
- Analyst target
- $70.50 (-2.8%)
- Consensus
- Hold · 24 analysts
Momentum is working in TECH's favour - it ranks in the upper part of DailyIQ's momentum universe. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.
Reverse DCF
What growth is priced into TECH?
At today's price, Bio-Techne Corporation needs to grow free cash flow about 32.8% a year for the next 10 years to justify its valuation at a 10.21% cost of capital. Over its actual history it has compounded free cash flow at 6.5% a year, so the market is asking for 26.2 percentage points above its own delivered rate. On that basis TECH looks priced above what its own growth record supports.
- Implied FCF growth
- 32.8%
- Historical FCF CAGR
- 6.5%
- Growth gap
- +26.2 pts
- Verdict
- RICH
- Discount rate (WACC)
- 10.21%
- Beta
- 1.02
Behaviour On Record
What TECH's own history says about today's numbers
- Realized volatility (21d)
- 2.1% 0th pct
- Below its peak
- -46.2%
- vs 200-day average
- +16.0%
- Up days (1y)
- 51%
Bio-Techne Corporation is currently running 2.1% annualised volatility over the last 21 sessions. Measured against TECH's own 13 years of daily returns rather than a market-wide average, that is the 0th percentile — unusually subdued by its own history, against a typical reading of 26.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
TECH is trading -46.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -21.4%, and the deepest was -43.1% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +16.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 81st percentile — a wider gap than this stock usually carries. Over the past year TECH closed higher on 51% of sessions, and it is currently 1 session into a falling streak.
On October specifically: over 13 years of records, TECH finished the month higher 7 of 13 times, with a median return of +1.1% and an average of -1.1%. Its strongest month historically has been July at +4.7% on average, its weakest August at -3.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: TECH has opened more than 2% away from the prior close in 148 of 3,267 sessions (4.5% of the time), with the largest gaps running +9.7% and -16.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against TECH's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of TECH's sector?
Bio-Techne Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, TECH ranks 9th of 15 tracked industries, improving.
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 91
- Industry rank
- #9 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on TECH?
Wells Fargo most recently downgraded Bio-Techne Corporation to Equal-Weight on Aug 13, 2026 with a price target of $73 (from $62). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.
- Latest action
- Wells Fargo — Equal-Weight
- 90-day upgrades
- 0
- 90-day downgrades
- 1
- Net rating momentum
- -1
Peers & ETF holders
TECH peers & ETF holders
BiotechnologyMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▼ Sell | 17,810,878 | 11.35% | $1.05B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 14,025,816 | 8.94% | $990.92M | 2026-08-07 |
| FMR LLC (Fidelity) | ▲ Buy | 12,794,784 | 8.15% | $903.95M | 2026-08-13 |
| Goldman Sachs Group Inc | ▲ Buy | 7,343,324 | 4.68% | $518.81M | 2026-08-14 |
| Morgan Stanley | ▼ Sell | 6,374,717 | 4.06% | $450.37M | 2026-08-13 |
| Geode Capital Management, LLC | ▲ Buy | 5,351,464 | 3.41% | $377.54M | 2026-08-12 |
| Invesco Ltd. | ▲ Buy | 4,986,424 | 3.18% | $352.29M | 2026-08-14 |
| Ruane, Cunniff & Goldfarb L.P. | ▼ Sell | 3,348,841 | 2.13% | $236.60M | 2026-08-14 |
| Neuberger Berman Group LLC | ▼ Sell | 2,844,692 | 1.81% | $200.98M | 2026-08-13 |
| Capital Research Global Investors | ▼ Sell | 2,621,890 | 1.67% | $185.24M | 2026-08-12 |
| Whitebox Advisors LLC | ▲ New | 2,100,001 | 1.34% | $148.37M | 2026-08-14 |
| JPMorgan Chase & Co | ▲ Buy | 1,862,805 | 1.19% | $132.60M | 2026-08-12 |
| Maverick Capital Ltd | ▼ Sell | 1,535,610 | 0.98% | $108.49M | 2026-08-14 |
| AllianceBernstein L.P. | ▼ Sell | 2,002,026 | 1.28% | $104.63M | 2026-08-14 |
| Norges Bank | ▼ Sell | 1,413,639 | 0.90% | $99.87M | 2026-08-12 |
| Northern Trust Corp | ▼ Sell | 1,311,188 | 0.84% | $92.64M | 2026-08-13 |
| Millennium Management LLC | ▲ Buy | 989,033 | 0.63% | $69.88M | 2026-08-14 |
| Citadel Advisors LLC | ▲ Buy | 965,918 | 0.62% | $68.24M | 2026-09-02 |
| Bank of America Corp | ▼ Sell | 955,237 | 0.61% | $67.49M | 2026-08-14 |
| Balyasny Asset Management L.P. | ▲ Buy | 836,870 | 0.53% | $59.12M | 2026-08-14 |
| Capital World Investors | ▲ Buy | 536,962 | 0.34% | $37.94M | 2026-08-12 |
| Soros Fund Management LLC | ▲ New | 535,400 | 0.34% | $37.83M | 2026-08-14 |
| Pentwater Capital Management LP | ▲ New | 500,000 | 0.32% | $35.33M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 445,145 | 0.28% | $31.45M | 2026-08-03 |
| Verition Fund Management LLC | ▲ Buy | 438,746 | 0.28% | $31.00M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2026-04-08 | 2026-05-06 |
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2026-03-26 | 2026-04-06 |
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2026-02-24 | 2026-03-10 |
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2026-01-28 | 2026-02-02 |
| April McClain Delaney | House | MD06 | ▲ Buy | $1K - $15K | 2025-12-02 | 2026-01-05 |
| April McClain Delaney | House | MD06 | ▲ Buy | $1K - $15K | 2025-10-22 | 2025-11-04 |
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2025-08-01 | 2025-09-02 |
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2025-05-26 | 2025-07-02 |
| April McClain Delaney | House | MD06 | ▲ Buy | $1K - $15K | 2025-04-09 | 2025-05-02 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-04-01 | 2025-05-14 |
| Thom Tillis | Senate | NC | ▼ Sell | $1K - $15K | 2015-02-13 | 2015-02-26 |